Emgality Approved for Migraine Prevention—Lilly Says Free for Some Insured Patients
- Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults. PR Newswire. Available at https://www.prnewswire.com/news-releases/lillys-emgality-galcanezumab-gnlm-receives-us-fda-approval-for-the-preventive-treatment-of-migraine-in-adults-300720720.html. Accessed 9/28/18.
- Emgality label. Available at http://pi.lilly.com/us/emgality-us-ppi.pdf. Accessed 9/28/18.
- Highleyman L. Galcanezumab Offers Help for Cluster Headache and Migraine. Available at https://www.medpagetoday.com/meetingcoverage/ahs/73836. Accessed 9/28/18.